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Abstract
Background: ZIP8 functions endogenously as a Zn
+2/HCO3
- symporter that can also bring cadmium (Cd
+2) into the
cell. It has also been proposed that ZIP8 participates in Cd-induced testicular necrosis and renal disease. In this
study real-time PCR, western analysis, immunostaining and fluorescent localization were used to define the
expression of ZIP8 in human kidney, cultured human proximal tubule (HPT) cells, normal and malignant human
urothelium and Cd
+2 and arsenite (As
+3) transformed urothelial cells.
Results: It was shown that in the renal system both the non-glycosylated and glycosylated form of ZIP8 was
expressed in the proximal tubule cells with localization of ZIP8 to the cytoplasm and cell membrane; findings in line
with previous studies on ZIP8. The studies in the bladder were the first to show that ZIP8 was expressed in normal
urothelium and that ZIP8 could be localized to the paranuclear region. Studies in the UROtsa cell line confirmed a
paranuclear localization of ZIP8, however addition of growth medium to the cells increased the expression of the
protein in the UROtsa cells. In archival human samples of the normal urothelium, the expression of ZIP8 was
variable in intensity whereas in urothelial cancers ZIP8 was expressed in 13 of 14 samples, with one high grade
invasive urothelial cancer showing no expression. The expression of ZIP8 was similar in the Cd
+2 and As
+3
transformed UROtsa cell lines and their tumor transplants.
Conclusion: This is the first study which shows that ZIP8 is expressed in the normal urothelium and in bladder
cancer. In addition the normal UROtsa cell line and its transformed counterparts show similar expression of ZIP8
compared to the normal urothelium and the urothelial cancers suggesting that the UROtsa cell line could serve as a
model system to study the expression of ZIP8 in bladder disease.
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Cadmium is ranked 7
th in the “Top 20 Hazardous Sub-
stances Priority List “ by the Agency for Toxic Substance
and Disease Registry and the U.S. Environmental Protec-
tion Agency [1]. Individuals at the highest risk for cad-
mium-related disease include cigarette smokers, those on
a steady diet rich in high fiber foods or contaminated shell-
fish, women having low body-iron stores, and malnour-
ished populations [2-5]. In acute doses, Cd
+2 has been
shown to cause damage to the central nervous system,
lung, bone, gastrointestinal tract, liver, ovary, testis, pla-
centa, and the developing embryo [6,7]. Chronic exposure
to low amounts of Cd
+2 has been shown to cause renal
proximal tubular metabolic acidosis and osteomalacia
(renal Fanconi syndrome) [8]. The elimination of Cd
+2
from the body is very slow and thus accumulates as a total
body burden, predominantly in the kidney, with age. Cad-
mium is also classified as a human “Category 1” carcino-
gen due to its strong correlation with lung cancer [5,9-11].
Association of Cd
+2 with cancers of other organs have also
been suggested, but the data are currently inconclusive.
This laboratory has been interested in the possible associ-
ation of Cd
+2 with the development and progression of
human urothelial cancer. There is an extremely strong as-
sociation of human bladder cancer with the consumption
of cigarettes and tobacco, with some reports suggesting a
two- to four-fold increased risk and that 50% of the blad-
der cancers in men would not occur in the absence of
cigarette smoking [12,13]. The number of cigarettes
smoked, degree of inhalation, type of tobacco, use of filters,
and smoking cessation have all been shown to have spe-
cific relationships with the development of bladder cancer
[14]. Cigarette smoke is by far one of the greatest sources
of Cd
+2 exposure with each cigarette containing between
1–2 μgo fC d
+2 and 40-60% of the Cd
+2 in inhaled smoke
enters the systemic circulation [7,13-17]. The high level of
Cd
+2 accumulation in individuals who smoke cigarettes,
along with the strong association of bladder cancer and
smoking, is a major factor indirectly implicating Cd
+2 in
the development of urothelial cancer. There are also sev-
eral epidemiological studies which have implicated Cd
+2 in
the development of bladder cancer [5,9,18,19].
This laboratory has developed a model of Cd
+2 and As
+3
induced human urothelial cancer through the direct malig-
nant transformation of the UROtsa cell line, a cell line
retaining characteristics of human urothelium [20,21]. This
laboratory has also been interested in As
+3, a bladder car-
cinogen highly implicated in the incidence of bladder can-
cers due to human exposure in drinking water [22-24], and
have developed an in vitro bladder carcinogenesis model
for As
+3 similar to that of Cd
+2.T h eA s
+3-transformed cells
serve as an interesting control to that transformed by Cd
+2,
due to the divergent chemical properties of As
+3.T h e
laboratory has subsequently isolated and characterized 6
additional Cd
+2 transformed cell lines and 5 additional
As
+3 transformed cell lines [25-27]. These cell lines were all
shown to retain morphological characteristics consistent
with human urothelial cancer and to display phenotypic
differences characteristic of tumor heterogeneity. The hist-
ology of subcutaneous tumor transplants produced by
these transformed isolates displayed histological features of
human urothelial carcinoma with areas of squamous differ-
entiation. This observation is important since urothelial
carcinoma is the most prominent type of bladder cancer in
western countries and accounts for over 95% of all cases
and is 5
th in overall occurrence [28]. To the authors’ know-
ledge, there has been no examination of the mechanism by
which Cd
+2 might enter the urothelial cell in order to elicit
cell transformation. Recent studies have shown a relation-
ship between a specific allelic difference in the mouse
Slc39a8 gene encoding the ZIP8 transporter and the spe-
cific phenotypes of Cd-induced testicular necrosis and
acute renal failure [29,30]. Subsequent studies have shown
that the ZIP8 transporter, which is utilized by Cd
+2 for
transport can also transport one or more essential divalent
cation(s) that are critical to cellular function [31]. In cell
culture studies, manganese (Mn) was shown to be the best
inhibitor of ZIP8-mediated Cd
+2 uptake; possessing a low
Km of 2.2 μM. These studies show that ZIP8 is a Cd
+2 or
Mn
+2/HCO3
- symporter, but a role for the transport of Zn
+2
cannot be ruled out. ZIP8 has been localized to the apical
surface of two cell types; between the blood and vascular
endothelial cells of the testis [29,30], and between the
glomerular filtrate and renal proximal tubule cells [30].
ZIP8 has also been shown to exist in glycosylated and non-
glycosylated forms [30,31] and can alter their localization
as a function of extracellular Zn
+2 concentration [32]. The
role of ZIP transporters in cadmium damage to the testis
and kidney has been the subject of a recent review [33].
The finding that the ZIP8 transporter can transport Cd
+2
into several cell types suggested that this transporter might
also be operative in the urothelial cell. The first goal of the
present study was to determine the expression and
localization of ZIP8 in HPT cells since the in situ expres-
sion of ZIP8 has previously been shown for this cell type.
The second goal was to determine if ZIP8 was expressed in
normal human urothelium and if expression was altered in
human urothelial cancer. The final goal of the study was to
determine ZIP8 expression and localization in human
urothelial cells transformed by Cd
+2 and As
+3.
Results
Expression and localization of ZIP8 in human kidney and
cultured HPT cells
The ZIP8 protein has been previously reported to be
expressed in the proximal tubule of the mouse kidney and
to exist in glycosylated and non-glycosylated forms [30,31].
In the present analysis, this observation was extended
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histochemisty was used to determine the expression
and localization of ZIP8 protein in paraffin-embedded,
formalin-fixed, patient archival specimens. Serial sec-
tions of the kidney specimens were cut and stained for
ZIP8, aquaporin-1 and calbindin. Three independent
specimens of human kidney were examined and all
demonstrated expression of ZIP8 in the proximal and dis-
tal tubules (Figure 1A). The illustration shown is typical of
all 3 independent samples which showed strong staining of
the distal tubules and moderate to strong staining of the
proximal tubules. Glomeruli were negative for ZIP8 stain-
ing in all samples which served as an additional negative
control, over that of staining with primary and secondary
antibody alone. Staining for aquaporin-1 (proximal tubule
specific marker) (Figure 1B) and calbindin (distal tubule
specific marker) (Figure 1C) confirmed the identification
of the different tubules. Western analysis was performed
on protein extracts prepared from the three samples of
human renal cortex. The results of this analysis showed
that whole cell extract of normal renal cortex displayed
three bands reactive with the ZIP8 antibody (Figure 2A).
The three ZIP8 protein bands had molecular weights cor-
responding to approximately 80, 49 and 43 kDa. Real-time
PCR and western analysis was also performed on extracts
of 3 isolates of HPT cells. The expression of ZIP8 mRNA
was similar among all three cell isolates and well below
that of the β-actin gene, having about 25 ZIP8 transcripts
for every 1,000 transcripts of β-actin (Figure 2B). Western
analysis (Figure 2D) showed the presence of two
bands of ZIP8, one corresponding to a molecular
weight of 80 kDa and the other 49 kDa. The expres-
sion of the 49 kDa band was much higher than that
of the 80 kDa ZIP8 band. In contrast to that found in
renal tissue, there was no evidence of the 43 kDa
ZIP8 protein band in extracts of the HPT cells. Im-
munofluorescence confocal microscopy was used to
localize the ZIP8 protein in the HPT cells. The results
of this analysis showed that the ZIP8 protein was
localized at two distinct cellular locations within the
population of HPT cells (Figure 3). The first, which
was the dominant pattern, showed localization of the
ZIP8 protein in a punctate pattern that extended
throughout the cytoplasm of the cell with an
increased concentration along the periphery of the ap-
ical face of the cell (Figure 3A, C, E). The punctate
cytoplasmic localization is consistent with presence in
the endoplasmic reticulum (ER) and the peripheral
staining indicates localization to the cell membrane.
The second pattern noted in fewer cells showed a
similar localization of the ZIP8 protein throughout
the cytoplasm consistent with localization to the ER.
However, in these cell profiles, a distinct concentra-
tion of ZIP8 staining was localized to the paranuclear
region of the cell and not to the periphery of the cell
(Figure 3B, D, F).
Expression and localization of ZIP8 in human urothelium,
urothelial cancer and parental UROtsa cells
Immunohistochemisty was also used to determine the ex-
pression and localization of ZIP8 protein in paraffin-
embedded, formalin-fixed, patient archival specimens of
normal human urothelium and urothelial cancer. Five in-
dependent specimens of normal urothelium were exam-
ined for the expression and localization of the ZIP8
protein. The specimens of “normal” urothelium were arch-
ival specimens from patients undergoing surgical interven-
tion for bladder cancer and showed no cancer involvement
on hematoxylin and eosin (H&E) examination of the tissue
sections. The ZIP8 protein was shown to be expressed in
the urothelial cells of all five specimens of normal bladder;
however, the expression in the urothelial cells was variable
among the specimens (Figure 1D, E, F). One specimen was
shown to have weak expression of ZIP8 in the urothelium
(Figure 1D), three specimens had moderate expression
(Figure 1E) and one specimen showed strong staining for
ZIP8 (Figure 1F). Within each specimen, ZIP8 staining of
the urothelial cells was uniform among the cells. There
were occasional spindle cells in the lamina propria that
showed weak ZIP8 staining, but otherwise the majority
of stromal cells showed no staining for ZIP8. The immu-
nohistochemical analysis of ZIP8 was also informative
regarding the localization of ZIP8 in normal urothelium.
Low power microscopic examination suggested, in
addition to localization in the cytoplasm, a paranuclear
localization of ZIP8 staining in the urothelial cells and this
was confirmed by examination at higher powers of light
level microscopic examination (Figure 1G). This finding
was consistent for all five specimens of normal urothelium.
Western analysis was used to determine the expression of
the ZIP8 protein in extracts prepared from 4 independent
samples of normal human urothelium. These samples were
obtained as medical waste without patient identifiers from
surgically removed bladder cancer specimens following
completion of diagnostic protocols in surgical pathology.
The specimens were selected by the attending pathologist
to be areas of the urothelium removed from those areas of
the bladder having urothelial cancer. This analysis showed
that all 4 specimens displayed the 49 kDa band identified
as the non-glycosylated form of the ZIP8 protein
(Figure 2E). None of the 4 samples of normal urothelium
showed the presence of the higher molecular weight
80 kDa protein band associated with the glycosylated form
of ZIP8 (Figure 2E). Cytosolic and membrane extracts
were also prepared from parental UROtsa cells and west-
ern analysis was performed on the protein samples. The
analysis showed that all the three forms of ZIP8 protein
(80, 49 and 43 kDa) were present in the whole cell extract
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the 49 kDa bands were found to be associated with the
membrane preparation.
Immunohistochemistry was also employed to examine
the expression of ZIP8 in a small set of urothelial cancers.
The expression and localization of ZIP8 was determined in
Figure 1 Immunoperoxidase staining of ZIP8 in normal kidney and urothelium. A. Normal kidney. Staining of ZIP8 in the distal tubule (#) is
stronger compared to the proximal tubules (+), whereas the staining is absent in the glomerulus (−). B and C. Serial section of the normal kidney
stained for aquaporin-1 (B), a proximal tubule specific marker and calbindin (C), a distal tubule specific marker. (+) indicates proximal tubules and
(#) indicates distal tubules. D-G. Staining of ZIP8 in the normal human urothelium. D. The urothelium from bladder shows weak staining of ZIP8
(+), mainly in the intermediate layers; the most superficial umbrella cells are negative for ZIP8 (arrows). Some spindled stromal cells in lamina
propria are weakly positive for ZIP8 (*). E. The urothelium from renal pelvis shows moderate staining of ZIP8 in the intermediate layers (+); the
staining of the most superficial umbrella cells (arrows) is much weaker than the intermediate layers. The asterisks indicate stromal tissue in lamina
propria, which shows no staining of ZIP8. F. Strong staining of ZIP8 in the urothelium (+). Some scattered stromal cells in lamina propria are also
positive for ZIP8 (*). G. Higher magnification of D, displaying paranuclear staining of ZIP8 in the cells of intermediate layers of urothelium (+). The
umbrella cells are almost negative for ZIP8 (arrows). Asterisks mark the stromal cells in lamina propria with weak staining of ZIP8.
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at the apical face (A, C, E) which is the dominant localization observed. The second is a concentration of ZIP8 in the paranuclear region (B, D, F).
All HPT cells showed ZIP8 extending throughout the cytoplasm in a punctate pattern consistent with the endoplasmic reticulum. ZIP8 staining is
shown in green while the nuclear dye To-PRO-3 iodide is shown in red. Single Z-series slices are shown in A and B while orthogonal views in the
X- and Y-planes are shown in C, D and E, F respectively. Bar=10 μm and represents the scale for both A and B.
Figure 2 Expression of ZIP8 in the human kidney and bladder. A. Western analysis of ZIP8 protein in cortical tissue of the human kidney. B
and D. Expression of ZIP8 in cultured HPT cells. B. Real-time PCR analysis of ZIP8 mRNA. D. Western analysis of ZIP8 protein. C. Western analysis of
ZIP8 protein in cultured UROtsa parent cell. E. Western analysis of ZIP8 protein in normal human urothelium tissue.
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cimens displayed diffuse weak to moderate staining for
ZIP8 (Figure 4A-D) and they also displayed moderate
paranuclear staining for ZIP8 (Figure 4E). The stromal ele-
ments of the 4 specimens were uniformly negative for ex-
pression of ZIP8. Nine cases of high grade urothelial
cancer were also examined for ZIP8 expression. Three
cases were high grade non-invasive urothelial carcinomas
and two of them displayed uniform diffuse weak staining
of ZIP8 while the other displayed moderate, but focal, dif-
fuse cytoplasmic staining for ZIP8 (Figure 5A, B, C). The
stromal cells in each of these 3 cases of high grade, non-
invasive urothelial cancer did not stain for ZIP8. Six cases
of high grade, invasive urothelial cancer were examined for
the expression of ZIP8 (Figure 5D-I). The expression of
ZIP8 among these six cases covered a spectrum of expres-
sion, with one case having no expression (Figure 5D), two
cases showing weak staining (Figure 5E, F), one case with
moderate to strong staining (Figure 5G), and two cases
with strong staining (Figure 5H, I). The expression was dif-
fuse within the cytoplasm of all these cases. The tumor
stroma in these six cases was mostly negative for ZIP8 ex-
pression, but an occasional stromal cell could be found
that was weakly positive. None of the cases of high grade
urothelial cancer displayed paranuclear staining of ZIP8.
Expression and localization of ZIP8 in parental and Cd
+2
and As
+3 transformed UROtsa cells
Real-time PCR was employed to determine the expression
of ZIP8 mRNA in the parental UROtsa cell line and in the
6A s
+3 and 7 Cd
+2 transformed cell lines (Figure 6A). This
analysis showed that expression of ZIP8 mRNA in the par-
ental UROtsa cell line was on the order of 1 transcript for
every 1,000 transcripts of β-actin mRNA. The expression
Figure 4 Immunoperoxidase staining of ZIP8 in low grade urothelial carcinoma. A. Weak staining of ZIP8 (+) in low grade urothelial
carcinoma. Asterisks (*) indicate stromal tissue which is negative for ZIP8. B. low grade urothelial carcinoma of bladder showing weak focal
staining of ZIP8 (+). There are areas of the tumor that show negative staining for ZIP8 (−). Asterisks (*) indicate stromal tissue which is negative for
ZIP8. C. Low grade urothelial carcinoma from renal pelvis with moderate staining of ZIP8 (+). The tumor stroma is negative for ZIP8 (*). D.
Moderate staining of ZIP8 (+) in low grade urothelial carcinoma. Asterisks (*) indicate stromal tissue which is negative for ZIP8. E. Higher
magnification of D showing paranuclear staining of ZIP8 (+). Asterisks (*) indicate stromal tissue which is negative for ZIP8.
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pared to the parental cells in all the cell lines transformed
by As
+3 or Cd
+2. Western analysis was employed to deter-
mine the level of ZIP8 expression in the parental and As
+3
and Cd
+2 transformed cell lines. Preliminary determina-
tions showed a wide variability in the expression of the
ZIP8 protein in the parental UROtsa cells. To explore this
variability, ZIP8 protein was determined by western ana-
lysis on parental cultures of UROtsa cells at 8, 16, 24, 36
and 48 hours (hrs) following the addition of fresh growth
media. The results of this analysis demonstrated that the
expression of the 49 kDa ZIP8 protein in the parental
UROtsa cells was increased markedly 8 hrs and 16 hrs fol-
lowing the addition of fresh growth media to the cells, with
a return to near pre-feeding levels by 24 hrs post-feeding
(Figure 6B, D). A minor band consistent with the 80 kDa
protein could be seen 16 hrs following addition of fresh
growth media. An identical analysis on the transformed
lines showed that ZIP8 mRNA expression was unaffected
by the change in growth medium, remaining at levels not
significantly different from that shown in panel A (Fig-
ure 6A). The 7 isolates of Cd
+2 transformed UROtsa cells
and the 6 As
+3 transformed isolates were found to have no
alterations in ZIP8 protein expression following replenish-
ment of the growth media (data not shown). The expres-
sion of ZIP8 protein was determined in the 7 isolates of
Cd
+2 transformed UROtsa cells and the 6 As
+3 trans-
formed cell lines (Figure 6C, E). All the isolates were
shown to express both the 49 kDa and 80 kDa protein
bands, with the 49 kDa band being the most prominent.
The expression of ZIP8 in the transformed isolates was
compared relative to the parental UROtsa cells 24 hrs fol-
lowing replenishment of the growth medium. Using this
time point for comparison, the data shows all but one iso-
late (As#3) to have increased expression of the 49 kDa
ZIP8 protein.
The intracellular localization of the ZIP protein was
determined by immunofluorescent analysis and confocal
microscopy in the parental UROtsa cells and their Cd
+2
and As
+3 transformed counterparts. The results of
Figure 5 Immunoperoxidase staining of ZIP8 in high grade urothelial carcinoma. A & B. Noninvasive urothelial carcinoma showing weak
staining of ZIP8 (+). Asterisks (*) indicate stromal tissue which is negative for ZIP8. C. Noninvasive urothelial carcinoma with focal moderate
staining of ZIP8 (+). Asterisks (*) indicate stromal tissue which is negative for ZIP8. D. Invasive urothelial carcinoma with negative staining of ZIP8
(−). Few smooth muscle fibers between the invasive tumor nests are weakly positive for ZIP8 (*). E. Invasive urothelial carcinoma with focal weak
staining of ZIP8 (+). Asterisks (*) indicate stromal tissue which is negative for ZIP8. F. Invasive urothelial carcinoma with weak staining of ZIP8 (+).
A few spindled shaped stromal cells are also weakly positive for ZIP8 (*). G. Anaplastic urothelial carcinoma showing moderate staining for ZIP8
(+). Asterisks (*) indicate stromal tissue which is negative for ZIP8. H. Invasive urothelial carcinoma with moderate to strong staining of ZIP8 (*). A
few spindled shaped stromal cells are weakly positive for ZIP8 (*). I. Poorly differentiated urothelial carcinoma with strong staining for ZIP8 (+).
Asterisks (*) indicate stromal tissue which is negative for ZIP8.
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+3 and Cd
+2 and their corresponding tumor heterotransplants. A.
Real-time PCR analysis of ZIP8 mRNA in As
+3 and Cd
+2 transformed cell lines. The analysis was done in triplicates and the results are expressed as
mean transcript number per 1000 transcripts of β-actin. * Statistically significant compared to parental UROtsa cells. B and D. Effect of feeding on
the expression level of ZIP8 protein in UROtsa parent cells. B. Mean (±) IOD values are for lower bands representing the 49 kDa form of ZIP8. C
and E. Western analysis of ZIP8 protein in UROtsa cells transformed by As
+3 and Cd
+2. Mean (±) IOD values are for lower bands (D) representing
the 49 kDa form of ZIP8. F, G and H. Expression of ZIP8 in tumor heterotransplants. F. Real-time PCR analysis of ZIP8 mRNA. G and H. Western
analysis of ZIP8 protein. Mean (±) IOD values are for lower bands representing the 49 kDa form of ZIP8.
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lines showed that ZIP8 had a punctate pattern that
extended throughout the cytoplasm, consistent with the
ER, with a concentration in the paranuclear region of the
majority of the cells (Figure 7). The intracellular localization
of ZIP8 was similar between the parent (Figure 7A, D, G)
and As
+3 (Figure 7B, E, F) or Cd
+2 (Figure 7C, F, I) trans-
formed UROtsa cell lines although the transformed cells
were more likely to have at least some apical localization of
ZIP8 in addition to the strong paranuclear localization.
These staining patterns are consistent with the staining that
was seen in the HPTcells.
Real-time PCR and western analysis was also employed
to determine ZIP8 mRNA and protein expression in
extracts prepared from subcuteneous tumor transplants
produced in immune compromised mice from each of the
Cd
+2 and As
+3 transformed cell lines (Figure 6F, G, H).
This analysis demonstrated that all the tumor transplants
expressed ZIP8 mRNA and the 49 kDa ZIP8 protein. None
of the tumor transplants were shown to express the
80 kDa band associated with the glycosylated form of
ZIP8. Immunohistochemistry was employed to examine
the expression of ZIP8 in the tumor transplants. The
results showed that the staining pattern was similar be-
tween and among the tumor transplants generated from
the Cd
+2 and As
+3 transformed cell lines (Figure 8A-D). In
all the tumors, the well-differentiated urothelial cells in the
center of the tumor nests showed absent or very weak
staining for ZIP8 while the peripheral less differentiated
tumor cells showed moderate to strong staining in the
cytoplasm. There was no evidence of paranulear staining
of ZIP8 in any of the tumor transplants. Some spindle
shaped stromal cells between the tumor nests also stained
weakly for ZIP8.
Discussion
The first goal of the present study was to determine the
expression and localization of ZIP8 in HPT cells. These
cells were chosen for analysis since the in situ expression
of ZIP8 has previously been shown for this cell type along
with an association of ZIP8 with Cd-induced damage to
the proximal tubule [29-33]. In addition, the renal MDCK
cell line, which retains the property of vectorial active
transport, has been used to characterize the localization
and expression of ZIP8 [30-32]. An analysis of the expres-
sion of ZIP8 in the HPT cells largely confirmed what has
been found in previous studies employing the MDCK cell
line [30-32]. The HPT cells were shown to express two
forms of the ZIP8 protein, one at approximately 49 kDa
and the other at approximately 80 kDa. The 49 kDa band
identified by the ZIP8 antibody is in agreement with the
molecular weight expected for the non-glycosylated ZIP8
protein as derived from the sequence available from the
NCBI database. The human 49 kDa band identified as
ZIP8 in the HPT cells is also in general agreement with
that obtained for MDCK cells transfected with the mouse
ZIP8 sequence [31]. The approximate 80 kDa band found
in extracts of the HPT cells is assumed to be the glycosy-
lated form of the ZIP8 protein. This is based on the mo-
lecular weight and association with the membrane fraction
of the HPT cell extracts, findings similar to that found for
the MDCK cells transfected with the mouse ZIP8
sequence [31]. The ZIP8 protein was also localized to the
endoplasmic reticulum and apical cell surface of the HPT
cells, an identical localization to that found for the ZIP8-
transfected MDCK cells [31]. The finding that there were
occasional profiles of HPT cells with paranuclear staining
of ZIP8 defines a difference in ZIP8 localization compared
to the MDCK cells. There are also findings in other organs
Figure 7 Immunofluorescent localization of ZIP8 in UROtsa parent and transformed cell lines. ZIP8 was found to concentrate heavily in the
paranuclear region of the cells along with a punctate staining that extended throughout the cytoplasm, indicative of association with the
endoplasmic reticulum. The parent UROtsa cells are shown in A, D, G while the transformed cells As#5 are shown in B, E, H and Cd#7 are shown
in C, F, I. ZIP8 staining is shown in green while the nuclear dye To-PRO-3 iodide is shown in red. Single Z-series slices are shown in A - C while
orthogonal views in the X- and Y-planes are shown in D-F and G-I respectively. Bar=10 μm and represents the scale for A - C.
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show different localizations of ZIP8 and higher molecular
weights for the glycosylated form of ZIP8 [34,35]. The sig-
nificance of glycosylated and non-glycosylated forms is
interpreted to reflect processing of the ZIP8 protein for de-
ployment to the plasma membrane. Glycosylation occurs
on asparagines (N-linked) initially in the ER. There are no
consensus O-linked glycosylation sites in the protein. Final
processing of N-linked glycosyl groups on proteins occurs
in the Goli apparatus [36,37]. Confocal localization sug-
gests that the protein has considerable ER distribution,
and this would be consistent with the 49 kDa form. It is
possible that when the initial glycosylation begins, the N-
linked glycosyl groups are not enough to significantly in-
crease the molecular weight of the protein and/or to retard
the mobility of the protein on a Western blot. The 43 kDa
band, corresponding to isoform C which has the first 67
amino acids missing, part of which is the signal peptide,
and is predicted not to be transported into the lumen of
the ER for glycosylation.
The results of an analysis of ZIP8 in protein extracts of
human renal tissue were similar to that of the HPT cells,
showing both a 49 kDa and 80 kDa band that was reactive
with the ZIP8 antibody. There was also an additional, ap-
proximately 43 kDa band in the human renal tissue extract
that was reactive with the ZIP8 antibody. This band could
be a degradation product due to the processing interval
between surgical removal and tissue procurement or it
could be an additional isoform of the ZIP8 protein that
has a predicted molecular weight 43.1 kDa by NCBI and
identified as ZIP8 isoform 2 on the Swiss-Prot database.
This 43.1 kDa band was also found in extracts of normal
urothelial tissue. The 43 kDa band was not found in
extracts of HPTcells or the parental UROtsa cell line. Pre-
vious studies have shown ZIP8 to be expressed only in the
proximal tubules of the kidney in mice [30]. However,
immuno-staining of ZIP8 on archival specimens of human
kidney showed ZIP8 to be present in both proximal and
distal tubule cells and in some stromal elements in normal
urothelium, presenting the possibility of isoform 2 being
present in other tubule segments and/or stromal cell types.
This discrepancy between mice and human expression
patterns could be due to specie specific differences. Over-
all, the results in the HPTcells regarding the expression of
ZIP8 were largely those expected from previous studies.
This is important due to the implication of ZIP8 in
enhanced cadmium-induced renal proximal tubular dam-
age in mice [30]. The HPTcells have been used as a model
for the study of Cd-induced toxicity in the past [38-41]
and the current observation that they have basal expres-
sion of ZIP8 should provide the research community with
an effective in vitro model to further elucidate the role of
ZIP8 in Cd-induced proximal tubule renal damage.
The second goal of the present study was to determine if
ZIP8 was expressed in normal human urothelium and if
expression was altered in human urothelial cancer. The
results demonstrated that ZIP8 was expressed in the nor-
mal urothelium. Immunostaining showed that ZIP8 was
Figure 8 Immunoperoxidase staining of ZIP8 in tumor heterotransplants. A. UT As#1. B. UT As# 5. C. UT Cd#1. D. UT Cd#7. The well-
differentiated cells in the center of tumor nests show no staining or very weak staining of ZIP8 (#), while the peripheral less differentiated tumor cells
show moderate to strong staining for ZIP8 (+). A few spindled shaped stromal cells between the tumor nests show weak staining for ZIP8 (*).
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mens of normal urothelium. However, the expression of
ZIP8, while uniform within each specimen, was highly vari-
able among the five samples, with staining for ZIP8 varying
from very weak to strong in intensity. Immunostaining also
showed ZIP8 to have a paranuclear localization in addition
to punctate staining within the cytoplasm. Western analysis
of ZIP8 expression in 5 independent specimens of normal
urothelium showed the presence of the 49 kDa band, but
not the higher molecular weight band associated with the
glycosylated form of the ZIP8 protein. The corresponding
analysis of ZIP8 expression in the UROtsa cell line is of
interest regarding the variabili t yo fe x p r e s s i o na n dt h ep a r a -
nuclear localization of ZIP8 in the normal urothelium.
First, the level of expression of the ZIP8 protein in the
UROtsa cell line was shown to be dependent on the time
following replenishment of the growth medium, with
expression being elevated significantly following feeding of
the cells with fresh growth medium, followed by a rapid
reduction in expression within 36 hrs of the addition of
f r e s hg r o w t hm e d i u m .I th a sa l s ob e e ns h o w nt h a tt h e
availability of Zn
+2 can influence the trafficking of the ZIP8
protein to the apical cell surface in MDCK cells [32]. One
can speculate that the variability of expression of ZIP8
demonstrated among the independent specimens of nor-
mal urothelium may reflect differences in the nutritional
status of the patient from which the samples originate.
The possibility that ZIP8 expression can vary with nutri-
tional status would render interpreting differences in
expression between levels in tissues and fluids from nor-
mal versus disease states very difficult. Second, the ZIP8
protein was also localized to the paranuclear region of the
parental UROtsa cells, a finding in agreement with the
paranuclear localization of the ZIP8 protein in the five
patient samples of normal urothelium. The association of
ZIP8 protein with the cell nucleus could indicate a possible
involvement in providing Zn
+2 to Zn-requiring transcrip-
tion factors. The present findings appear to be the first de-
scription of ZIP8 expression and localization in human
urothelium.
As part of the above goal it was also proposed to deter-
mine if ZIP8 expression was altered in human urothelial
cancer. As noted above, the wide variability of expression
of ZIP8 in normal urothelium renders comparison very
difficult between the normal and malignant urothelial cells.
The most striking finding from the analysis was that out of
the 14 cases of low and high grade urothelial cancer exam-
ined for ZIP8 expression, there was one high grade, inva-
sive urothelial cancer that showed no expression of the
ZIP8 protein. An additional difference in the expression of
ZIP8 among the urothelial cancers was that there was no
paranuclear localization of ZIP8 in any of the high grade
urothelial cancers that showed positive staining for ZIP8.
Otherwise, expression in the remaining high and low grade
cancers displayed a wide variability of ZIP8 expression
similar to that noted in specimens of normal urothelium.
The fact that the one urothelial cancer that did not express
the ZIP8 protein was in the high grade invasive group
could be important since the loss of ZIP8 could be asso-
ciated with tumor progression. This would need to be con-
firmed on a much larger sample set of urothelial tumors
having data on patient outcome.
The final goal of the study was to determine ZIP8 ex-
pression and localization in human urothelial cells trans-
formed by Cd
+2 and As
+3. The results showed that both
Cd
+2 and As
+3 transformed UROtsa cells and their tumor
transplants expressed higher levels of ZIP8 mRNA and
protein compared to the parental cell line. There was no
notable difference in the expression of ZIP8 between the
Cd
+2 and As
+3 transformed cell lines, ruling out a Cd
+2
specific alteration in ZIP8 expression that might be asso-
ciated with the development of urothelial cancer. One dif-
ference noted between the As
+3 and Cd
+2 transformed cell
lines compared to the parental UROtsa cell line was that
the transformed lines consistently expressed the 80 kDa
band of ZIP8 associated with the glycosylated form of the
protein. The parental UROtsa cell line displayed the
80 kDa band only transiently after the cells were fed fresh
growth medium. The transformed cell lines also showed
some localization of ZIP8 to the cell membrane, but the
majority was localized to the cytoplasm and paranuclear
region of the cells. Again, these differences are difficult to
interpret due to the time dependence of ZIP8 expression
with growth medium replenishment in the parental
UROtsa cell line. Similar to that found for the archival spe-
cimens of high grade urothelial cancer, the tumor trans-
plants generated from the As
+3 and Cd
+2 transformed cells
showed no evidence of paranuclear staining for ZIP8.
It remains to be elucidated why or how ZIP8 is overex-
pressed in metal transformed cells. It was unexpected that
As
+3-transformed cells also over-express this transporter.
As
+3 is not expected to be transported by ZIP8 due to the
divergent properties of these metals. As
+3 exists as a trihy-
droxylated, neutral species known as arsenous acid As(OH)
3 with the pK for the donation of the first hydrogen being
greater at pH 9.0 [42], and is thought to be transported via
the aquaporin transporters [43,44]. It is well known that
global gene expression patterns are considerably altered
during metal carcinogenesis, and that alterations in epigen-
etic regulation have been appreciated to play a fundamental
role [45]. Epigenetic alterations leading to the overexpes-
sion or silencing of specific loci have been correlated to
methylation/demethylation of CpG islands and post-trans-
lational modifications of histone tails within the promoters
of altered genes. Specific explanations for why particular
loci are silenced or conducive to overexpression by long-
term exposure and/or transformation by metals still remain
to be determined, although in a few specific cases,
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demethylases have be identified. Epigenetics alterations are
thus suspected in the case of ZIP8 overexpression in Cd
+2-
and As
+3-transformed cells. It is tempting to speculate that
specific metal transport pathways may be involved.
Conclusions
The study is the first to show that ZIP8 is expressed in
normal urothelium. ZIP8 was also shown to be expressed
in 13 of 14 urothelial cancers; with one high grade, invasive
urothelial cancer being negative for ZIP8 expression. ZIP8
was shown to have a paranuclear localization in normal
urothelium, but not in high grade urothelial cancers. The
parental UROtsa cell line and its As
+3 and Cd
+2 counter-
parts showed a similar pattern of ZIP8 expression when
compared to the normal urothelium and urothelial cancers
and should provide a human model system to study ZIP8
expression in bladder disease. The study also shows that
the HPT cells should provide an effective human in vitro
model system for the study of the role of ZIP8 in proximal
tubule damage by Cd
+2 and possibly other heavy metals.
Methods
Cell culture
Stock cultures of HPT cells for use in experimental proto-
cols were grown using serum-free conditions in a 37°C, 5%
CO2:95% air atmosphere as previously described by this
laboratory [46,47]. The cells were fed fresh growth
medium every 3 days, and at confluence, the cells were
subcultured using trypsin-EDTA (0.05%, 0.02%). Stock cul-
tures of the parental UROtsa cell line were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing
5%v/v fetal calf serum in a 37°C, 5% CO2:95% air atmos-
phere [21]. The isolation and growth of the 7 isolates of
the Cd
+2 transformed UROtsa cells and 6 isolates of the
As
+3 transformed UROtsa cells have been described previ-
ously [25-27]. They were grown and maintained using
identical conditions. Confluent flasks were sub-cultured at
a 1:4 ratio using trypsin-EDTA (0.05%, 0.02%) and the cells
were fed fresh growth medium every 3 days.
Human and tumor transplant tissue for
immunohistochemistry, real-time PCR and western
analysis of ZIP8 expression
T i s s u ef o rt h ei m m u n o h i s t o chemical analysis of ZIP8
expression in human bladder were obtained from arch-
ival paraffin blocks that originated from previously com-
pleted patient diagnostic procedures. These archival
specimens contained no patient identifiers and use was
approved by the University of North Dakota Internal Re-
view Board. Fresh and paraffin-embedded, formalin-
fixed tumor samples originating from the As
+3 and Cd
+2
transformed UROtsa cell lines were pre-existing speci-
mens from previous studies [21,25,26]. Human kidney
and urothelial tissue used for real-time PCR analysis and
western analysis of ZIP8 mRNA and protein expression
were obtained as medical waste from surgical specimens
following completion of all diagnostic protocols. These
specimens contained no patient identifiers and use was
approved by the University of North Dakota Internal
Review Board.
Expression of ZIP8 mRNA and protein in tissue and cell
culture preparations
The preparation of total RNA and protein from cultured
cells and tissues has been described previously [21,25,26].
For the isolation of cytosolic and membrane associated
proteins, the tissue was snap frozen in liquid nitrogen and
was ground to a fine powder. Proteins were extracted from
the powdered tissue by dissolving it in T-PER reagent
(Thermo Scientific, Rockford, IL) and the DNA was
sheared by passing the tissue extract through a 23-gauge
needle. The tissue extract was centrifuged at 16,000×g for
20 minutes at 4°C. Isolation of the membrane and cyto-
solic fractions was carried out by centrifuging the super-
natant at 100,000 g for 30 minutes at 4°C in a TLA-100.3
rotator (Beckman TL100) ultracentrifuge. The clear red
supernatant representing the cytosolic fraction was dec-
anted. The light-brown pellet representing the membrane
fraction was rinsed and resuspended in T-PER reagent.
Protein concentration was determined by the bicinchoni-
nic acid (BCA) protein assay (Pierce Chemical Co., Rock-
ford, IL) before 100 mM dithiothreitol (DTT) was added
to each sample.
The expression of ZIP8 mRNA was determined using
real-time RT-PCR and ZIP8 specific primers were obtained
from Qiagen (Valencia, CA). Briefly, 1 μg of purified RNA
was subjected to complementary DNA (cDNA) synthesis
using the iScript cDNA synthesis kit (Bio-Rad Laborator-
ies, Hercules, CA) in a total volume of 20 μL. Real-time
PCR was performed utilizing the SYBR Green kit (Bio-Rad
Laboratories) with 2 μL of cDNA, 0.2 μM primers in a
total volume of 20 μL in an iCycler iQ real-time detection
system (Bio-Rad Laboratories). Amplification was moni-
tored by SYBR Green fluorescence. The level of ZIP8
mRNA was determined relative to that of UROtsa cells
grown in serum-containing medium using serial dilutions
of this sample as the standard curve. The resulting relative
levels were then normalized to the fold change in β-actin
expression assessed by the same assay using the primers,
sense: CGACAACGGCTCCGGCATGT and antisense:
TGCCGTGCTCGATGGGGTACT, giving a product size
of 194 base pairs and with the cycling parameters of
annealing/extension at 62°C for 45 seconds and denatur-
ation at 95°C for 15 seconds.
The expression of ZIP8 protein was determined by west-
ern blotting. Briefly, protein samples (20 μg) were separated
on a 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide
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membrane (Amersham Biosciences, Piscataway, NJ). Mem-
branes were blocked in Tris-buffered saline (TBS) contain-
ing 0.1% Tween-20 (TBS-T) and 5% (wt/vol) nonfat dry
milk for 1 hr at room temperature. After blocking, the
membranes were probed with the ZIP8 primary antibody
(0.18 μg/ml) in blocking buffer for 1 hr at room
temperature. The primary antibody for the monitoring of
ZIP8 expression was an affinity purified rabbit polyclonal
antibody produced by Open Systems, Inc (Huntsville, AL)
using the peptide sequence QNGHTHFGNDNFGPQEKTH
previously described in the literature to generate an anti-
body specific for ZIP8 [34]. After washing 3 times with
TBS-T, the membranes were incubated with the anti-rabbit
secondary antibody (1:2000) in antibody dilution buffer for
1 hour. The blots were visualized using the Phototope-HRP
(horseradish peroxidase) Western blot detection system
(Cell Signaling Technology, Beverly, MA).
Immunohistochemical analysis of ZIP8 expression
Tissues were routinely fixed in 10% neutral buffered for-
malin for 16–18 hours. All tissues were transferred to 70%
ethanol and dehydrated in 100% ethanol. Dehydrated tis-
sues were cleared in xylene, infiltrated, and embedded in
paraffin. Tissue sections were cut at 3–5 μm for use in
immunohistochemical protocols. Prior to immunostaining,
sections were immersed in preheated citrate buffer pH 6.0
and heated in a steamer for 20 minutes. The sections were
allowed to cool to room temperature and immersed into
TBS-T (Dako, Carpinteria, CA) for 5 minutes. The ZIP8
antibody was used at 0.45 μg/ml. Liquid diaminobenzidine
was used for visualization. Slides were rinsed in distilled
water, dehydrated in graded ethanol, cleared in xylene, and
coverslipped.
Immunolocalization of ZIP8 in human proximal tubule
and UROtsa cells
The cells were grown in 24 well plates containing
12 mm glass coverslips at 37°C, 5% CO2. Cells at conflu-
ent density were then fixed and stained using previously
described procedures [25,26]. Briefly, cells were fixed in
3.7% buffered, methanol-free formaldehyde (Poly-
sciences, Inc, Warrington, PA) for 15–20 minutes at
room temperature. Coverslips were then quenched of
free aldehyde with 0.1 M NH4Cl for 15 minutes, fol-
lowed by permeabilization with 0.1% Saponin for
10 minutes. Cells were stained for ZIP8 by incubation
for 45 minutes at room temperature with 9.0 μg/ml
ZIP8 antibody. The ZIP8 primary antibody was detected
by incubating cells with 2.7 μg/ml of Alexa-Fluor 488
goat anti-rabbit antibody (Invitrogen, Carlsbad, CA) for
45 minutes at room temperature. Controls consisted of
coverslips treated with the secondary antibody only. All
controls stained appropriately and had virtually no
staining when photographed under the same settings
that were used for experimental cells. For experiments
determining the localization of ZIP8 near the nucleus,
staining was carried out as indicated above followed by
staining with a 5 μM solution of To-PRO-3 iodide (Invi-
trogen) for 45 minutes at room temperature. All cover-
slips were mounted in ProLong Gold anti-fade reagent
with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen) for
nuclear counter staining. Cells were observed and images
captured using a Zeiss LSM 510 Meta Confocal Microscope
with LSM 510 software (Carl Zeiss MicroImaging Inc).
Images were obtained by capturing z-slices at a depth of
0.5 μm. DAPI images of the same fields were captured by
epifluorescence.
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